panitumumab
amgen,takeda
['paradigm']
paradigm trial conclusions at the 2022 plenary. game changing? share your thoughts #asco22 
Narjust Duma, MD, (@NarjustDumaMD) #LCSM Oncologist from @DanaFarber, takes over our Twitter today to discuss #ASCO22.